摘要
背景:由于其优异的生物相容性和生物降解性,聚ε-己内酯及其衍生物共聚物作为药物载体在药物和医学领域得到广泛研究,特别是用于控制释放抗肿瘤药物。基于聚ε-己内酯的药物递送系统导致主要优点,包括均匀的药物分布,长期的降解和药物释放过程,无毒性和与身体组织的细胞相容性。由美国食品和药物管理局批准,聚ε-己内酯为具有可控药物释放行为的抗肿瘤药物输送系统的设计和制造提供了有希望的平台。 方法:这一微型审查集中在最近在应用基于聚ε-己内酯的材料用于癌症治疗药物的控制释放方面的进展。对科学网络进行了仔细的搜索,主要集中在2013年至2016年发表的相关论文中。 结论:在该微型评估中总结了应用聚ε-己内酯控制递送和靶向释放化学抗肿瘤药物的最新进展。受益于世界各地科学家的努力,已经评估了基于不同配方的聚ε-己内酯相关材料的各种化疗药物递送系统。已经广泛认识到,将聚ε-己内酯成分引入药物递送系统中将增加药物负载能力,减少渗漏,延长释放时间并导致可释放速率。特别是随着环境响应性输送系统(pH-,热,磁场和光响应性药物载体)的发展,可以实现增强的肿瘤细胞靶向潜能以及降低的全身毒性。
关键词: 聚ε-己内酯,可生物降解,控制释放,抗肿瘤,靶向,药物递送。
图形摘要
Current Cancer Drug Targets
Title:Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Volume: 17 Issue: 5
关键词: 聚ε-己内酯,可生物降解,控制释放,抗肿瘤,靶向,药物递送。
摘要: Background: Due to their excellent biocompatibility and biodegradability, poly-epsiloncaprolactone and its derivative copolymers have been extensively studied as drug carriers in pharmaceutical and medical fields, especially for controlled release of anti-tumor drugs. Poly-epsiloncaprolactone based drug delivery systems lead to major advantages including uniform drug distribution, long term of degradation and drug release process, non-toxic in nature and cyto-compatible with body tissues. Approved by US Food and Drug Administration, poly-epsilon-caprolactone provides a promising platform for design and fabrication of anti-tumor drug delivery systems with controllable drug release behaviors.
Methods: This mini-review focused on the recent progress in application of poly-epsiloncaprolactone based materials for controlled release of cancer therapy drugs. A careful search was performed on web of science, mainly focused on the related papers published from 2013 to 2016. Conclusion: Recent advances in applying poly-epsilon-caprolactone for controlled delivery and targeting release of chemical anti-tumor drugs were summarized in this mini-review. Benefited from the efforts of scientists all over the world, various chemotherapeutic drug delivery systems based on different formulations of poly-epsilon-caprolactone related materials have been evaluated. It has been widely recognized that the introduction of of poly-epsilon-caprolactone components into drug delivery systems would increase drug loading capacity, decrease leakage, prolong releasing period and result in controllable releasing rate. Especially with the development of environment-responsive delivery systems (pH-, thermo-, magnetic field- and light-responsive drug carriers), enhanced tumor cell targeting potential, as well as decreased systemic toxicity would be realized.Export Options
About this article
Cite this article as:
Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs, Current Cancer Drug Targets 2017; 17 (5) . https://dx.doi.org/10.2174/1568009617666170109150430
DOI https://dx.doi.org/10.2174/1568009617666170109150430 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Bisindolylmethane as an Important Scaffold for Drug Discovery
Current Medicinal Chemistry Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Antiviral and Virucidal Activities of Natural Products
Current Medicinal Chemistry Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer
Current Cancer Therapy Reviews Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Metformin Protects the Brain Against the Oxidative Imbalance Promoted by Type 2 Diabetes
Medicinal Chemistry Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Current Status of Magnetite-Based Core@Shell Structures for Diagnosis and Therapy in Oncology Short running title: Biomedical Applications of Magnetite@Shell Structures
Current Pharmaceutical Design Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Current Alzheimer Research Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension
Current Cancer Drug Targets Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design 1,4-Benzothiazines-A Biologically Attractive Scaffold
Mini-Reviews in Medicinal Chemistry The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Coumarins as Antioxidants
Current Medicinal Chemistry